Lawton, Michael http://orcid.org/0000-0002-3419-0354
Ben-Shlomo, Yoav
Gkatzionis, Apostolos
Hu, Michele T.
Grosset, Donald
Tilling, Kate
Funding for this research was provided by:
Parkinsons UK (J-1403, J-1101)
Medical Research Council (MC_UU_00011/3)
Article History
Received: 27 April 2023
Accepted: 21 December 2023
First Online: 28 January 2024
Declarations
:
: Michael Lawton—received fees for advising on a secondary analysis of an RCT sponsored by North Bristol NHS trust. Yoav Ben-Shlomo—Reports no disclosures. Apostolos Gkatzionis—Reports no disclosures. Michele T. M. Hu—received funding/grant support from Parkinson’s UK, Oxford NIHR BRC, University of Oxford, CPT, Lab10X, NIHR, Michael J Fox Foundation, H2020 European Union, GE Healthcare and the PSP Association. She also received payment for Advisory Board attendance/consultancy for Lundbeck, ESCAPE Bio, Evidera, Manus Neurodynamica, Biogen MA, CuraSen Therapeutics, Roche Products Ltd. She is an advisory founder of NeuHealth Digital Ltd (company number: 14492037), a digital biomarker platform to remotely manage condition progression for Parkinson’s. Donald G. Grosset—received payment for advisory board attendance from BIAL Pharma, Britannia Pharmaceuticals, and consultancy fees from the GM clinic. Grant support from Parkinson’s UK, the Neurosciences Foundation, and Michael’s Movers. Kate Tilling—Reports no disclosures.
: The Oxford Discovery cohort was approved by NRES Committee, South Central Oxford A Research Ethics Committee, Reference number 16/SC/0108. The Tracking Parkinsons cohort was approved by West of Scotland Research Ethics Service (WoSRES) reference 11/AL/0163.